Intended for healthcare professionals


Benzodiazepines and hip fractures in elderly people: case-control study

BMJ 2001; 322 doi: (Published 24 March 2001) Cite this as: BMJ 2001;322:704
  1. Corinne Pierfitte, registrara,
  2. Gerard Macouillard, consultantb,
  3. Michel Thicoïpe, consultantc,
  4. Anicet Chaslerie, registrara,
  5. Fabienne Pehourcq, consultanta,
  6. Myriam Aïssou, research assistanta,
  7. Béatrice Martinez, laboratory techniciana,
  8. Rajaa Lagnaoui, registrara,
  9. Annie Fourrier, research epidemiologista,
  10. Bernard Bégaud, professora,
  11. Jacques Dangoumau, professor,
  12. Nicholas Moore (nicholas.moore{at}, professora
  1. a Département de Pharmacologie, Unité de Pharmacologie Clinique, Centre Hospitalier Universitaire de Bordeaux, 33076 Bordeaux Cedex, France
  2. b Département d'Anesthésie-Réanimation, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux
  3. c Services des Urgences, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux
  1. Correspondence to: N Moore, Department of Pharmacology, Victor Segalen University, 33076 Bordeaux Cedex, France


    Objective: To determine whether benzodiazepines are associated with an increased risk of hip fracture.

    Design: Case-control study.

    Participants: All incident cases of hip fracture not related to traffic accidents or cancer in patients over 65 years of age. 245 cases were matched to 817 controls.

    Setting: Emergency department of a university hospital.

    Main outcome measures: Exposure to benzodiazepines and other potential risk or protective factors or lifestyle items.

    Results: The use of benzodiazepines as determined from questionnaires, medical records, or plasma samples at admission to hospital was not associated with an increased risk of hip fracture (odds ratio 0.9, 95% confidence interval 0.5 to 1.5). Hip fracture was, however, associated with the use of two or more benzodiazepines, as determined from questionnaires or medical records but not from plasma samples. Of the individual drugs, only lorazepam was significantly associated with an increased risk of hip fracture (1.8, 1.1 to 3.1).

    Conclusion: Except for lorazepam, the presence of benzodiazepines in plasma was not associated with an increased risk of hip fracture. The method used to ascertain exposure could influence the results of case-control studies.

    What is already known on this topic

    Benzodiazepines increase the risk of elderly people falling in a dose dependent way

    Their role in hip fracture remains disputed, with increased risk sometimes attributed to drugs with a longer half life or those used to induce sleep

    What this study adds

    Benzodiazepines were not associated with hip fracture either as a group or according to half life or to characterisation as hypnotic or anxiolytic

    Patients using two or more benzodiazepines may be at higher risk

    Patients using lorazepam or certain other benzodiazepines may also be at a higher risk of fracture


    Hip fracture is common in elderly people, resulting in important morbidity and mortality. Hip fracture is usually due to the combination of an acute event, usually a fall, with a chronic condition, such as osteoporosis. Risks can therefore pertain to falling1 or to a propensity to fracture after a fall.2 Many risk factors for hip fracture have been proposed or recognised, such as increasing age, low body weight, low intake of calcium and dairy products, age at menopause, number of children, osteoporosis, and a personal and family history of fractures. 3 4 Associated diseases, handicaps, and drugs could also play a part. The use of certain psychotropic drugs such as tricyclic antidepressants and selective serotonin reuptake inhibitors has been suggested as a risk factor for falling and hip fractures. 1 5 The role of benzodiazepines is more disputed: some studies have found an association between benzodiazepines, especially the longer acting ones, and hip fracture 3 6 7 and others have not. 8 9 Studies have also related hip fracture with dosage of benzodiazepine rather than the half life of the various formulations.10 Some of these discrepancies could be related to difficulties in ascertaining exposure especially in elderly people, in part because of cognitive factors, which may also by themselves be a risk factor for falling and could influence the use of benzodiazepines. 11 12 One study found that falls in elderly people were associated with the presence of benzodiazepines in blood, but it did not consider fractures.13 We therefore aimed to determine the association between benzodiazepines and other factors with the risk of hip fracture in elderly people, taking into account cognitive aspects and the status of exposure as ascertained from the presence of benzodiazepines in blood.

    Participants and methods

    From January 1996 to July 1997 we assessed all patients aged over 65 presenting to the emergency departments of the Pellegrin and Saint André university hospitals in Bordeaux, France, for inclusion in our study. A blood sample was obtained at admission after informed written consent had been obtained. The samples were frozen for later analysis.

    Cases were all elderly people admitted to the hospitals with acute hip fracture resulting from a fall that was not associated with cancer, a traffic accident, or aggression. Hip fracture was ascertained from x ray films and orthopaedic consultation.

    Controls were elderly people admitted to the same hospitals for acute disease without hip fracture not known to be associated with the use of benzodiazepines, a contraindication, or a disorder of equilibrium. Controls were matched with cases for age (within 5 years), sex, and week of admission. We attempted to match each case with four controls.

    Our study was designed to detect a twofold increase in risk with an α risk of 0.05 and a β risk of 0.10 (90% statistical power). Assuming a 20% exposure rate in the control population and a 4 to 1 control to case ratio, this required 300 cases and 1200 controls.

    Our study was approved by the regional ethics committee and registered with the National Commission on Computers and Freedom. It was conducted according to good clinical practice and the declaration of Helsinki.

    Data retrieval and ascertainment

    Questionnaires were administered to cases and controls during an interview with a trained research assistant within a week of admission. Data were also retrieved from medical records; this included telephoning the patients' doctors.

    We retrieved data on age, sex, height, weight, body mass index, place of residence, marital status, address (by postal code), hospital, date and time of admission, and date and time of fracture. We also obtained data on a personal and family history of fracture, surgery, associated diseases, age at menopause, number of children, and diet, including the intake of dairy products (milk, yoghurt, cheese, and others), with use assessed from 0 (every day) to 3 (never)). We also considered physical impairments (sight, hearing) and dependency scores. We used the four item activities of daily living test for people living at home14 and Katz's six item activities of daily living score for those living in an institution.15 Additionally, the combined binary threshold scoring of individual items defined the presence or absence of dependence.

    We determined exposure to benzodiazepines in three ways: with a structured patient questionnaire during an interview with a research assistant,16 mentioning the brand names of all benzodiazepines marketed in France; by consulting medical records; and by assay of a plasma sample taken at admission for our study or for standard tests. Benzodiazepines in the plasma were identified by using high pressure liquid chromatography with diode array detection (HPLC-DAD, HP 1090, Hewlett-Packard) and quantified by high pressure liquid chromatography with ultraviolet detection. Exposure to benzodiazepines was defined as the use of a benzodiazepine at the time of fracture or admission to hospital or the presence of benzodiazepines in the plasma at admission. The use of other drugs was determined from the questionnaire and medical records but not from plasma samples.

    Data analysis

    We coded the data, input them into EpiInfo version 6.0, and analysed them with Excel, Systat, and Egret. We performed univariate analyses after a descriptive analysis, followed by multivariate conditional logistic regression with the significant univariate relation (at P<0.1) and then systematically determined the presence of benzodiazepines in plasma. We considered as significant a P value of less than 0.05 or an odds ratio with a 95% confidence interval that did not include 1.

    We applied Student's t test for normally distributed continuous variables; the Mann-Whitney U test for non-normally distributed continuous variables; Fisher's exact test for dichotomous variables, or the χ2 test for polychotomous variables; and conditional (matched) logistic regression for univariate and multivariate analysis.



    We identified 1136 patients (319 cases, 817 controls). We could find no matched controls for 74 cases: we therefore included 245 cases and 817 matched controls (3.3 controls per case) in our study.

    The median delay between fracture and admission to hospital was two hours, and over 65% of cases were admitted within three hours of known time of fracture. The time of admission showed a similar distribution for cases and controls (figure).


    Time of admission with hip fracture for 245 elderly patients and 817 matched controls

    Comparisons between cases with or without controls

    The greater the age of the patient the more difficult it was to find matched controls. Matching decreased from 100% for patients aged 65 to 70 to 44% for those over 90. Unmatched cases were older (88 (SD 4.7) v 81 (SD 6.8) years, P<0.001) and were more often female (99.6% v 76%, P<0.01) than matched cases. They were not, however, more exposed to benzodiazepines than matched cases, whether exposure was determined from plasma samples (34% v 34%), questionnaire (30% v 24%), or medical records (34% v 33%). Our results are derived from the cases with matched controls.

    Non-benzodiazepine risk or protective factors

    Although we matched cases and controls to within 5 years, cases were slightly older than controls (81 (6.8) v 79 (7.6) years, P<0.001), and age increased the risk of hip fracture within the matching interval (odds ratio 1.22, 95% confidence interval 1.14 to 1.29). The body mass index was lower in cases than in controls (index above 25: 0.43, 0.27 to 0.70). Cases and controls did not differ in lifestyle or family status; age at menopause; use of hormone replacement therapy; number of children; previous medical, surgical, or obstetric history; family history of fractures; use of alcohol, tobacco, and coffee; or dependency scores for either instrument. A low intake of dairy products was associated with hip fracture (odds ratio per point (scale 0-12 points) less use 1.1, 1.01 to 1.23). Mobility was significantly less in cases who lived in institutions than in their matched controls (71% v 45% normal mobility, P<0.001). The risk of hip fracture was increased with impaired hearing (1.56, 1.04 to 2.34) and deafness (2.42, 1.05 to 5.41). Similar proportions of cases (72%) and controls (70%) were able to complete the questionnaires.

    Mean number of non-benzodiazepine drugs used was similar in cases (4.2) and controls (4.1). The use of any diuretic was associated with a lower risk of hip fracture (0.71, 0.52 to 0.96). Tricyclic antidepressants (2.07, 1.12 to 3.82)—but not selective serotonin reuptake inhibitors—and antacids (2.24, 1.16 to 4.33) were associated with an increased risk of fracture.

    Use of benzodiazepines

    The use of benzodiazepines, whether determined from questionnaires, medical records, or blood samples, was not associated with an increased risk of hip fracture (table 1). Benzodiazepines were used by 34% of cases and 36% of controls, according to the questionnaire. They were mentioned in the medical records of 33% of cases and 29% of controls and were found in the blood samples of 36% of cases and 32% of controls.

    Table 1

    Conditional logistic regression analysis for use of benzodiazepines as determined by questionnaire, medical record, or plasma sample in 245 cases of hip fracture and 817 matched controls

    View this table:

    Duration of half life was not associated with hip fracture. More cases than controls reported using two or more benzodiazepines, compared with none or one (7.4% v 3.7% determined from questionnaires and medical records; 7.4% v 4.3% determined from blood samples). This reported risk was not significant when the data came from blood samples, which showed that even more controls than cases used two benzodiazepines (table 2).

    Table 2

    Number of benzodiazepines found in cases (n=245) and controls (n=817). Values are numbers (percentages)

    View this table:

    Only lorazepam in plasma was significantly associated with hip fractures (1.8, 1.1 to 3.1). Although clobazam, loprazolam, nitrazepam, and temazepam had similarly increased odds ratios, because there were few users of these drugs their larger confidence intervals included 1. The other benzodiazepines were not associated with an increased risk of hip fracture (table 3). Cases were similar to controls in plasma concentration of individual benzodiazepines and of all benzodiazepines (table 4).

    Table 3

    Presence of individual benzodiazepines in blood samples

    View this table:
    Table 4

    Plasma concentrations of benzodiazepines (μg/ml) with more than five users. Values are means (95% confidence intervals) unless stated otherwise

    View this table:

    Multivariate analysis including the significant risk or protective factors and benzodiazepine in plasma did not change the odds ratios from the univariate analyses. In particular, benzodiazepines in plasma were not associated with an increased risk of hip fracture (0.9, 0.5 to 1.5).


    Exposure to benzodiazepines does not increase the risk of hip fracture in people aged over 65. This applies to benzodiazepines regardless of half life.

    Hip fracture usually results from falls.17 Factors that influence the risk of hip fracture are those that influence the risk of falling (for example, tricyclics, vertigo) and the propensity of bone to break after a fall (for example, bone mineral density or a cushion of fat tissue). 1 2 4

    Age and other risk factors

    Hip fracture seems to be the main cause of admission to hospital in elderly people; we found it difficult to find people aged over 90 admitted to the emergency department for other reasons. Age probably increases both the risk of falling and the consequences of the fall. Most other factors that we found were associated with hip fracture were expected.3 Weight or body mass index are known protectors against hip fracture: poor nutrition influences both weight and bone density, and increased weight is an important factor in bone modelling and strength. Additionally, a good layer of subcutaneous fat protects the bone from fracture.18 The use of fewer dairy products related to less chronic intake of calcium, protein, and vitamin D was also associated with an increased risk of hip fracture. 19 20 Decreased mobility protected against hip fracture, presumably by decreasing the risk of falling.21 Sensory handicaps (vision, hearing) were associated with an increased risk of fracture. 17 22 Hearing loss may be associated with hip fracture because ossicular demineralisation denotes osteoporosis,23 and it may also be related to repeated orthostatic hypotension, itself a risk factor for falling.24 Additionally, decreased sensory input could lead to a decreased awareness of the environment, although we did not include fractures related to incidents involving vehicles.

    We also confirmed a protective effect from diuretics25 and an increased risk from tricyclic antidepressants 26 27 —but not selective serotonin reuptake inhibitors, unlike two previous studies. 5 27 The association of antacids with hip fracture may be related to the large quantities of aluminium they often contain, which interfere with calcium metabolism and make bone more fragile.28

    Our findings must, however, remain tentative for two reasons—firstly, the study of the associations (positive or negative) of various drug groups with hip fracture was not the main objective of our study, and, secondly, these could be confounded by the use of hospital controls with possibly a higher exposure to these drugs than the general population.

    Benzodiazepines overall

    We found no association between the use of benzodiazepines and an increased risk of hip fractures, whether the information on exposure came from questionnaires, medical records, or plasma samples. An increased risk of hip fractures of more than 1.5-fold associated with benzodiazepines seems improbable from the confidence intervals we obtained.

    The validity of our result depends on how much our control population is representative of the general population. Much has been said about the choice of controls from the community or hospital,29 including for the study of hip fracture.30 Because the controls were admitted to hospital they were obviously ill and therefore had a higher probability of using drugs, perhaps including benzodiazepines, than a healthy control population. This could reduce the ability to detect an association between benzodiazepines and hip fractures. The prevalence of benzodiazepine use in our control population was around 35%, higher than the 17% found by Kirby et al.31 However, in a representative cohort of people aged over 65 from the same region as our study who were not admitted to hospital,32 the overall use of benzodiazepines was greater than one third of the population33: at the latest ascertainment (A Fourrier, personal communication, 2000) 37% of elderly people living at home and 43% of living in institutions were taking benzodiazepines. These values are even higher than the ones found in our controls. Additionally, we excluded all patients admitted because of diagnosis associated with the use of psychotropic drugs. Finally, the use of community controls would not have been compatible with plasma sampling: to avoid bias related to sampling time we would have had to sample elderly people at home within the same time frame as the cases, including during the night.

    Number and type of benzodiazepines

    The association between reported use of two or more benzodiazepines and an increased risk of hip fracture became non-significant when we considered only benzodiazepines found in the blood samples. Two or more benzodiazepines were found in blood samples mostly of controls; this could indicate ascertainment bias or recall bias in cases compared with controls. Using objective data from blood samples avoided this bias.

    When individual benzodiazepines were considered, however, lorazepam, and also possibly temazepam,6 loprazolam, nitrazepam, and clobazam, were associated with hip fracture. The other benzodiazepines even seemed to have a non-significant protective effect. Although these drugs may be more sedative than others, we found no association with other sedative drugs used as hypnotics such as zolpidem and zopiclone. Half life, dose, or plasma concentrations, did not seem to account for these differences. These findings should remain tentative until a common factor is found between these “at risk” drugs and other benzodiazepines.

    We did not confirm the reported associations between hip fracture and longer life benzodiazepines or with greater doses,10 or the association between falls and the presence of benzodiazepines in serum found by Ryynanen et al.13 However, not all falls result in fracture, and the risk factors for fracture and falling could differ or interact: the contrast between the uniformity with which studies found that benzodiazepines dose dependently increased the risk of falling and the many contradictions between studies of hip fracture raise the possibility that benzodiazepines may exert a dual effect. They may on the one hand increase the risk of falling and on the other decrease the risk of fracture when the fall occurs, so that the final association would be a result of the relative influence of both effects. The protective effect could be related to the muscle relaxant property of benzodiazepines: falling while relaxed decreases the risk of injury. In our study only the controls used non-benzodiazepine myorelaxants. We could not find a study of the relative myorelaxant properties of the different benzodiazepines, but this could be an indication for future studies and may explain the apparent differences in risks between different benzodiazepines.

    Effects of ascertainment of exposure status

    Our study assessed dependency indices and dietary factors, which are usually not included in database studies, and ascertained exposure. Drug exposure is often difficult to confirm, especially in elderly people. Doctors are not always aware of their patients' complete drug regimen, and patients themselves may be unaware of what they take because of cognitive impairment or because they may receive drugs without their knowledge. This is especially true in elderly people and for hypnotic drugs. Therefore we used the presence of benzodiazepine in blood at the time of admission as our main measure of exposure. In this instance where the risk of benzodiazepines is thought to be associated with an immediate increased risk of falling, blood samples provide the best indication of exposure. Our detection method using high performance liquid chromatography with diode array detection is routinely used to identify the use of drugs. Its only drawback could be a relatively low sensitivity, and subtherapeutic blood concentrations may have been missed in certain cases. However, the detection and identification of a drug in a blood sample indicates clear current exposure to that drug. The main difference between our cases and controls was that a larger proportion of controls had two or more benzodiazepines in their blood. This could indicate that ascertainment bias increases apparent multidrug exposure in cases and confirms that hard data on exposure is needed.


    We thank the patients and the staff of the emergency department.

    Contributors: CP was in charge of the study, oversaw the recruitment and study of the patients and the input of the data, and participated in the analysis, especially the contrast between questionnaire and records and plasma samples. GM and MT had the original idea for the study and coordinated patient recruitment and the clinical part of the study, including obtaining all the blood samples. AC initiated the study in the department of pharmacology and wrote the protocol. FP and BM developed the plasma assay methods and performed the assays. MA is the research assistant who saw the cases and controls, administered the questionnaires, obtained the medical records, and checked and input all the data. AF contributed to the protocol, the data analysis, and the interpretation of the results, especially the analysis of the dependency data and the validation of control exposure. RL contributed to the analysis of data and to the development of the logistic regression models. BB verified the protocol, study plan, and selection criteria of cases and controls, developed the fundamental statistical approaches used in the initial analyses, and the evolution of the analysis in response to the reviewers' comments. JD originated and supported the study and attributed resources to the project. NM oversaw the study, analysed the data, and wrote the manuscripts; he will act as guarantor for the paper. All authors read, amended, and approved the final manuscript.


    • Funding This study was supported by a grant from the Agence du médicament, Paris, and by the department of Pharmacology, Victor Segalen University, Bordeaux, France.

    • Competing interests CP now works for SmithKline Beecham Vaccines in Belgium, which has no interest in benzodiazepines. AC now works for the French Social Security as Medical Inspector in Guérande (near Nantes).


    1. 1.
    2. 2.
    3. 3.
    4. 4.
    5. 5.
    6. 6.
    7. 7.
    8. 8.
    9. 9.
    10. 10.
    11. 11.
    12. 12.
    13. 13.
    14. 14.
    15. 15.
    16. 16.
    17. 17.
    18. 18.
    19. 19.
    20. 20.
    21. 21.
    22. 22.
    23. 23.
    24. 24.
    25. 25.
    26. 26.
    27. 27.
    28. 28.
    29. 29.
    30. 30.
    31. 31.
    32. 32.
    33. 33.
    View Abstract